Compatible solutes for biological stabilization
This solution leverages compatible solutes (CS) from extremophilic organisms to enhance the stability of biologicals under adverse conditions without altering their properties. Ideal for applications in plant seeds and human biologicals, it is currently at TRL 2.
Overview
Compatible solutes (CS) are naturally occurring stabilizing agents synthesized by various organisms, particularly extremophiles like halophilic bacteria and archaea, which thrive in extreme conditions. This solution utilizes CS to enhance the stability of biologicals, such as plant seeds and human biologicals, under unfavorable conditions without altering their inherent properties. By integrating preparations of CS or utilizing extremophilic cultures that produce high amounts of CS, this approach aims to significantly improve biological stability through passive or active incorporation into target cells or extracellular stabilization.
Technical specifications
- Compatible solutes (CS): Low-molecular-weight compounds with minimal interference in central metabolism.
- Source organisms: Halophilic bacteria and archaea, which synthesize CS to endure multiple stresses such as osmotic pressure, high temperature, desiccation, and UV radiation.
- Application methods: Mixing biologicals with CS, biomass, or lysates of halophilic microorganisms rich in CS.
- Target applications: Stabilization of plant seeds, human biologicals, and other sensitive biological materials.
Technology readiness level
Current development is at Technology Readiness Level 2, focusing on establishing a list of promising CS, verifying commercial CS capabilities, and testing halophilic prokaryote biomass in laboratory conditions. Future validation includes confirming effects under relevant conditions and providing a biological interpretation of CS action.
About Hebrew University of Jerusalem
The Hebrew University of Jerusalem is a comprehensive public research university with multiple campuses in Jerusalem and an agricultural campus in Rehovot. Its integration with Hadassah’s university hospitals enables clinical studies, access to varied patient populations, and co‑located research that accelerates translation. Industry engagement runs through Yissum, the university’s tech‑transfer company, managing IP, licensing, startup creation, and sponsored research agreements. Research is supported by competitive national funding and international programs, including European Union frameworks.
delivered to your inbox.